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Metastatic Renal Cell Carcinoma,
Clear Cell Type, of the Parotid
Gland:
A Case Report, Review of Literature, and
Proposed Algorithmic Approach to Salivary
Gland Clear Cell Neoplasms in Fine-Needle
Aspiration Biopsies
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Renal cell carcinoma (RCC), clear cell type, is a commonly
encountered metastatic tumor that can present at unusual ana-
tomic sites many years after the primary tumor resection. Non-
cutaneous metastasis to the parotid gland is unusual; however,
a number of cases of parotid RCC metastasis have been
reported. Fine-needle aspiration biopsy (FNAB) is regularly
utilized during the evaluation of salivary gland lesions, where
it has a high sensitivity, specificity, and accuracy; however,
the identification and definitive diagnosis of primary and meta-
static clear cell neoplasms is a potential diagnostic pitfall for
salivary gland FNAB. Here, we describe a case of RCC, clear
cell type, metastatic to the parotid gland that was diagnosed
entirely from FNAB cell block material, which is the first such
reported case to our knowledge. We review the literature for
cases of parotid RCC metastasis and focus on the utility of
FNAB for synchronous versus metachronous presentations.
Finally, we evaluate the differential diagnosis of clear cell
parotid lesions, including ancillary histologic studies, and
propose an algorithmic approach to clear cell neoplasms of the
salivary gland. Diagn. Cytopathol. 2014;42:974–983. VC 2014
Wiley Periodicals, Inc.
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Renal cell carcinoma (RCC) is the most common primary
neoplasm of the kidney and accounts for approximately
2% of all newly diagnosed cancers in the United States
each year.1 Several histologic RCC subtypes have been
described, including the clear cell type, which comprises
up to 70% of all RCC. RCC, clear cell type, has a known
propensity to metastasize, most commonly via direct inva-
sion of the renal veins and vena cava, with subsequent
hematogenous dissemination to the lungs; however,
unusual metastatic sites or late metachronous metastases
(>10 years) are not infrequent, and distant metastasis
may be the first clinical presentation of the tumor.2
RCC metastasis to the head and neck is rare, but more
than 30 cases of parotid metastases have been reported over
the past 50 years.3–33 Metastases account for only 1%–4%
of all salivary gland tumors, with the parotid being the
most common metastatic site.34 The majority of parotid
metastases originate from the skin (i.e., melanoma or squa-
mous cell carcinoma), while less than 3% come from the
kidney. Although metastatic renal tumors comprise only
approximately 0.1% of all salivary gland neoplasms, from
a pathologist’s standpoint, they are important to recognize
in order to alert clinicians to a possible occult primary or
more diffusely metastatic malignancy.
Fine-needle aspiration biopsy (FNAB) is commonly
used to evaluate salivary gland lesions prior to surgical
resection, with the main goal being to detect a malig-
nancy or exclude a neoplasm. A subsequent aim is to fur-
ther classify a lesion as benign, low-grade neoplasm, or
high-grade neoplasm, as this distinction is essential in the
surgical decision-making process. The sensitivity and
specificity of salivary gland FNAB is reportedly as high
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as 98% for both, with up to 97% concordance (accuracy)
between cytologic and subsequent histologic diagnoses.35
Despite its demonstrated utility, there are a number of
potential diagnostic pitfalls in the salivary gland FNAB,
including the discrimination of primary and metastatic
clear cell neoplasms.
Here, we report a case of metastatic RCC, clear cell
type, to the parotid gland diagnosed from FNAB cell
block material. We then review the literature for cases of
parotid RCC metastases, focusing on the usefulness of
FNAB. Finally, we consider the differential diagnosis of
salivary gland clear cell neoplasms and propose an algo-
rithmic approach to ancillary histologic studies for dis-




A 64-year-old man with a history of RCC status post left
radical nephrectomy 6 years prior presented to his general
practitioner for bilateral cerumen removal from his ears
and, on physical examination, was found to have a 1.0 3
1.0-cm firm, painless, mobile mass under his right ear.
The lesion had been present for several weeks, and the
patient denied any symptoms related to the mass (i.e.,
swelling, erythema, numbness, muscle weakness). He was
referred to otolaryngology for evaluation, and a computed
tomography (CT) scan of the head and neck demonstrated
a 1.4 3 1.3 3 1.0-cm soft tissue nodule in the right
parotid gland. The patient subsequently underwent FNAB
of the right parotid mass.
Right Parotid FNAB
FNAB was performed with a 24-gauge needle; a portion
of the biopsy sample was utilized to produce a SurePath
slide, and the remainder of the sample was made into a
cell block. The SurePath slide was insufficient for diagno-
sis, containing numerous neutrophils, eosinophils, and red
blood cells with only scant, nondiagnostic squamous and
epithelial tissue. Hematoxylin and eosin (H&E)-stained
sections of the cell block specimen revealed small, cohe-
sive clusters of medium-sized, polygonal tumor cells with
eosinophilic to clear (vacuolated) cytoplasm, distinct
eosinophilic cell borders, and pleomorphic nuclei with
vesicular chromatin and variably prominent nucleoli
(Fig. 1A). The cytoplasm of malignant cells was magenta
in periodic acid-Schiff (PAS)-stained sections and cleared
after treatment with diastase (Fig. 1E and F), indicating
cytoplasmic glycogen accumulation. Immunohistochemis-
try was positive for pan-cytokeratin (AE1/AE3/Cam5.2),
vimentin, RCC, and CD10 (focal) (Fig. 1B–D) but
negative for cytokeratin 7 (CK7), cytokeratin 20, calpo-
nin, and p63 (data not shown); CAIX was strongly
positive (Fig. 1G), and thyroid transcription factor 1
(TTF-1) was negative (data not shown).
Review of Prior Left Radical Nephrectomy Specimen
Given the histologic appearance of the tumor cells in the
parotid FNAB cell block specimen, as well as the corre-
sponding immunohistochemical and special staining
results, a diagnosis of metastatic clear cell RCC was
strongly suggested. Thus, we reviewed the patient’s left
radical nephrectomy specimen (6 years prior) for histo-
logic correlation. Grossly, a 9.5 3 6.0 3 6.0-cm yellow-
white mass was located in the mid to lower pole of the
kidney, with focal extension though the renal capsule but
without involvement of the renal hilum or vein. Micro-
scopically, the mass consisted of nests of medium-sized
polygonal cells with abundant clear cytoplasm, sur-
rounded by a network of thin-walled blood vessels, with
pleomorphic nuclei with variably vesicular chromatin and
prominent nucleoli (Fig. 1H). There was focal perirenal
adipose invasion but no renal vein invasion, and all final
surgical margins were negative. Taken together, these
findings support a diagnosis of RCC, clear cell type
(AJCC pathologic stage T3a).36
Follow-Up
A subsequent CT scan of the chest revealed multiple
bilateral pulmonary nodules, consistent with metastatic
disease (presumed RCC), and due to the asymptomatic
nature of the parotid mass, surgical intervention was
deferred. He was started on sunitinib (previously
SU11428), a multitargeted receptor tyrosine kinase inhibi-
tor, and 4 months later, a repeat CT scan of the chest
demonstrated interval decrease in the size of the bilateral
pulmonary nodules.
Materials and Methods
The FNAB specimen was placed immediately in CytoR-
ich Red Preservative in a SurePath vial for production of
a single SurePath slide by the PrepStain Slide Processor
(BD Biosciences, San Jose, CA). The remainder of the
cell pellet was resuspended in Histogel (Thermo Fisher
Scientific, Waltham, MA) prior to standard processing
into formalin-fixed, paraffin-embedded slides. H&E and
PAS staining (with and without diastase digestion) were
performed using routine laboratory methods. Immunohis-
tochemistry was performed by the Department of Pathol-
ogy Immunohistochemistry Laboratory at the University
of Michigan using a BenchMark ULTRA automated
stainer and the ultraView Universal DAB Detection Kit
(Ventana Medical Systems, Oro Valley, AZ). See Table I
for details about primary antibodies.
Case reports were identified via a PubMed search with
the terms “RCC” or “renal cell carcinoma” and “parotid,”
and additional case reports were then identified from their
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Fig. 1. Metastatic RCC, clear cell type, to the parotid. (A–G) FNAB cell block specimen, 4003 magnification: (A) hematoxylin and eosin (H&E), (B)
pan-cytokeratin, (C) vimentin, (D) RCC, (E) PAS, (F) PAS with diastase, and (G) CAIX. (H) Left radical nephrectomy specimen, H&E, 1003 magnifi-
cation. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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bibliographies. Only articles in English were selected, and
case reports without sufficient supporting information
were excluded. To compare the outcomes of FNAB in
reported parotid RCC cases, two-sample hypothesis test-
ing was performed using 2 3 2 contingency tables and a
two-tailed Fisher’s exact test (sum of small P values
method).
Discussion
From the English literature over the past 50 years, we
identified an additional 35 reported cases of metastatic
RCC to the parotid (Table II).3–33 Including our case, the
age at diagnosis ranged from 40 to 83 years. It was more
common in men than women (22 versus 13 cases, respec-
tively), mirroring the male predominance of RCC more
generally. Thirty-two cases involved only 1 side (14 on
the right and 18 on the left), while 3 were bilateral, and
the maximum tumor dimension ranged from 0.8 to 8.0
cm. Just less than half of the cases presented as synchro-
nous metastases, while 19 cases were discovered meta-
chronously; 1 case presented initially as a synchronous
metastasis and then 4 months later metastasized meta-
chronously to the contralateral parotid gland.15 The time
to metachronous metastasis ranged from 4 months to 19
years, consistent with RCC’s known propensity for late
metastasis.
In addition to our case, 18 cases had reported FNAB
results, including all but 2 in the past 20 years, reflecting
the central role for FNAB in screening salivary gland
lesions (Table III).17–20,23–33 Of these cases, 7 were syn-
chronous metastases, and 12 were metachronous metasta-
ses. Interestingly, there was a striking difference in the
sensitivity and specificity for FNAB diagnosis of parotid
RCC metastasis depending on whether the lesions were
synchronous or metachronous. Although nine (75%) of
the metachronous cases were correctly diagnosed as
malignant, only two (29%) of the synchronous cases were
appropriately identified as such (P5 0.074). The differ-
ence becomes even more pronounced if only the more
specific diagnosis of metastatic RCC is considered:
although eight (67%) of the metachronous metastases
were diagnosed correctly, none of the synchronous cases
were identified as metastatic RCC (P5 0.013). This may
simply reflect information bias (i.e., a rare diagnosis is
more likely to be made if the possibility of that diagnosis
is known to the pathologist); however, the fact that only
11 (58%) of the 19 cases were correctly classified as
malignant by FNAB and less than half were identified as
metastatic RCC underscores the diagnostic difficulty of
such lesions.
Of the eight cases that were not correctly reported as
malignant by FNAB, four were nondiagnostic, unsatisfac-
tory, or inconclusive; two were incorrectly diagnosed as
pleomorphic adenomas (PAs); and two were thought to
be negative (Table III).17,19,24,27–29,31,33 Three cases were
correctly classified as malignant, but a diagnosis of meta-
static RCC was not rendered: the first case showed malig-
nant lymphoma/leukemia in a patient with a history of
chronic lymphocytic leukemia (CLL); the second case
was incorrectly diagnosed as primary adenocarcinoma of
the parotid; and the third case was not further classified
(reported as “few malignant cells”).20,23,32 These results
suggest at least two possible sources of diagnostic diffi-
culty: (1) the adequacy of the FNAB specimen for diag-
nosis; and (2) the unbiased discrimination of metastatic
RCC from other primary or metastatic lesions of the
parotid (particular those with clear cell features).
The rate (21%) of inadequate or equivocal FNAB
specimens in our case report review is higher than the
reported frequencies in large salivary gland FNAB
cohorts, which can be as low as 3%.35 This likely reflects
the range of sampling methods, experience, and ability
across different institutions around the world over a
period of 20 years, but factors intrinsic to metastatic RCC
(i.e., tumor structure) may also contribute. Similar to
other case reports, our cytologic specimen was initially
nondiagnostic; however, the diagnosis of metastatic RCC
was ultimately made based on histopathologic features
and ancillary studies of the FNAB cell block specimen.
We note that none of the other FNAB cases reported uti-
lizing a cell block in addition to the standard cytologic
preparations, and thus to our knowledge, our case is the
first to diagnose parotid RCC metastasis from an FNAB
cell block specimen.
Because the majority of RCC are clear cell type, the
differential diagnosis of parotid RCC metastases includes
both primary and metastatic clear cell salivary gland
lesions, including (but not limited to) myoepithelial-
predominant PA, myoepithelioma, clear cell oncocytoma,
clear cell acinic cell carcinoma, myoepithelial carcinoma
(MC), epithelial-myoepithelial carcinoma (EMC), mucoe-
pidermoid carcinoma (MEC), primary clear cell carci-
noma (otherwise known as hyalinizing clear cell
Table I. Primary Antibodies
Antibody Concentration Vendor
Calponin pre-dilute Cell Marque (Rocklin, CA)
Carbonic anhydrase
IX (CAIX)
1:600 Novus Biological (Littleton,
CO)
CD10 pre-dilute Ventana Medical Systems









RCC pre-dilute Ventana Medical Systems
TTF-1 pre-dilute Cell Marque
Vimentin pre-dilute Ventana Medical Systems
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carcinoma), clear cell thyroid carcinoma, and melanoma.
The cytologic and histologic characteristics of these
lesions are described in detail elsewhere34,37,38; however,
we briefly highlight the salient cytomorphologic features
of these tumors here. In cytology preparations, PA is
often recognized by its biphasic population of duct epi-
thelial and myoepithelial cells and mesenchymal-like
stroma. Duct epithelial cells are medium-sized and round
to cuboidal, with small round nuclei and nucleoli, finely
granular chromatin, eosinophilic cytoplasm, and well-
defined cell borders. Myoepithelial cells, on the other
hand, show considerable cytomorphologic variability,
ranging in size from small to large with pleomorphic cel-
lular and nuclear features. Duct epithelial cells are often
tightly cohesive and form small tubules, while myoepithe-
lial cells are usually more loosely cohesive and can be
found either in small fascicles or as individual cells. The
other major component of PA—the mesenchymal-like
stroma—also demonstrates substantial variability, ranging
from paucicellular to hypercellular with myxoid, chon-
droid, or collagenous elements; in Papanicolaou-stained
smears, the stroma usually appears pale or eosinophilic,
while in Romanowsky-stained cytologic specimens, it has
a purple appearance.
Myoepithelial cells are a common feature of PA, myoe-
pithelioma, MC, and EMC. In some PA, the duct epithe-
lial cell population is only a minor component, and such
myoepithelial-predominant PA can be difficult to distin-
guish from myoepithelioma; although not strictly diagnos-
tic, the presence of mesenchymal-like stroma suggests
a diagnosis of PA. MC and EMC have similar overall
cytomorphologies to myoepithelioma and PA, respec-
tively, but there is marked nuclear pleomorphism and,
commonly, mitoses and intranuclear inclusions
(“pseudonucleoli”); these features should be sufficiently
worrisome as to warrant the consideration of a malignant
lesion (Fig. 2G and H).
Cytologic samples from oncocytoma are usually very
cellular, containing sheets or trabeculae of large, polygo-
nal cells with granular cytoplasm, well-defined cell
Table II. Summary of Case Reports
Reference Age (years) Gender Location Size (cm)a Chronicity Time to metachronous
Patey et al. 63 F Syn
Kucan et al. 55 M R Syn
Percival and Curt 71 F R 4 Syn
Sist et al. 62 M L 3 Syn
Smits and Slootweg 69 F R 2 Meta 9 years
Hessan et al. 52 M L Syn
Harrison et al. 60 F R 2/2/2 Meta 10/14 years
G€unbay et al. 60 M L 4 Meta 19 months
Melnick et al. 72 M L 8 Syn
Owens et al. 75 F L 3 Meta 8 years
Owens et al. 55 M R 4 Syn
Coppa and Oszczakiewicz 42 M L 4 Syn
Pisani et al. 59 M L 2 Syn
Sarangi and Hameed 71 M B Syn/Meta 4 months
Ravi et al. 55 F B 3 Meta 7 years
Borghi et al. 63 M R 2.5 Syn
Stanley et al. 71 F R Meta
Stanley et al. 40 M R Meta
Sykes et al. 59 L 3 Syn
Gangopadhyay et al. 48 M L 1.5 Syn
Vara et al. 55 M L 2 Meta 5/6 years
Adil et al. 52 M R 6 Meta 5 months
Kundu et al. 61 M R 2 Syn
Li et al. 63 M B 3/2.5 Meta 10/14 years
Park and Hlivkio 83 F L 2.5 Meta 10 years
G€og€us¸ et al. 59 F R 3 Meta 10 years
Seijas et al. 67 M L 2 Syn
Newton et al. 74 F R 1.5 Meta 7 years
Mrena et al. 76 F R Meta 9 years
Mrena et al. 62 M L 3 Meta 5 years
Mrena et al. 58 F R 0.8 Syn
Spreafico et al, 67 M R 6 Meta 18 months
Laco et al. 75 M R 3 Syn
Deeb et al. 82 M R 4 Meta 19 years
Lau et al. 79 F L 2 Meta 16 years
Udager and Rungta 64 M R 1.4 Meta 6 years
(40–83) (22 M, 13 F) (14 L, 18 R, 3 B) (0.8–8.0) (17 S, 20 M) (4 months–19 years)
M, male; F, female; R, right; L, left; B, bilateral; Syn, synchronous; Meta, metachronous.
aMaximum dimension.
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borders, small, round, centrally placed nuclei, and promi-
nent, cherry-red nucleoli. Well-differentiated acinic cell
carcinoma can have a similar appearance to oncocytoma;
however, acinic cell carcinoma lacks a prominent nucleo-
lus and typically forms loosely cohesive acinar-like clus-
ters (as opposed to sheets or trabeculae) (Fig. 2E). Acinic
cell carcinoma may be associated with dense lymphoid
infiltrates containing prominent germinal centers, but
mitoses and necrosis are uncommon features.
MEC has a diverse cytomorphology and consists of at
least four different types of malignant cells—mucin-
producing (goblet) cells, intermediate cells, squamous
(epidermoid) cells, and clear cells—the relative distribu-
tion of which varies with the tumor’s histologic grade.
Mucus-producing cells are medium to large with eccentric
nuclei and vacuolated cytoplasm. Intermediate cells vary
from small, basaloid-type to medium-sized, cuboidal-type
and demonstrate varying degrees of pleomorphism
depending on the histologic grade of the MEC. Squamous
cells have the appearance of mature squamous epithelial
cells. Clear cells are large, round cells with clear cyto-
plasm and small nuclei and nucleoli. Low-grade MEC is
often a paucicellular, polymorphic lesion, with a predomi-
nance of mucus-producing cells, variable numbers of
clear cells, and relatively few intermediate and squamous
cells; these features are nonspecific and can be difficult to
differentiate from a benign lesion, such as mucocele.
Intermediate-grade MEC is more cellular than its low-
grade counterpart and consists predominantly of interme-
diate and squamous cells (Fig. 2F); mucus-producing cells
are often seen as well, but clear cells are rare. High-grade
MEC is composed almost entirely of loosely cohesive,
pleomorphic cells, with focal areas of mucus-producing
and intermediate cells; the presence of these cell types in
a high-grade salivary gland lesion suggests the diagnosis
of MEC.
Clear cell thyroid carcinoma is a described variant of
papillary thyroid carcinoma (PTC); in cytologic speci-
mens, PTC cells are medium sized with characteristic
nuclear features, including molding and/or crowding,
grooves, pseudoinclusions, “powdery” chromatin, and
prominent nucleoli. The cytomorphology of melanoma,
on the other hand, is considerably variable but often dem-
onstrates poorly cohesive clusters of large, pleomorphic,
binucleated cells with eccentric nuclei and prominent
nucleoli (Fig. 2C and D). Although the presence of mela-
nin pigment (in combination with the aforementioned
cytologic features) suggests a diagnosis of melanoma,
approximately half of all melanomas are amelanotic; thus,
lack of melanin pigment does not exclude melanoma.
Finally, cytologic specimens from RCC, clear cell type,
are often very bloody and can range from paucicellular to
hypercellular. Tumor cells are usually large with irregu-
lar, indistinct cell borders, abundant clear or finely granu-
lar cytoplasm, small- to medium-sized eccentric nuclei,
and variably prominent nucleoli (depending on grade)
(Fig. 2A and B). On Romanowsky staining, pink, strand-
like fibrillary material is often seen and, when present, is
highly suggestive of a diagnosis of RCC.
In cases for which definitive tumor classification cannot
be made by standard cytologic and/or routine H&E cell
block specimen, ancillary studies may help to distinguish
between these entities (Table IV).34,39–46 On the basis of
these staining characteristics, we propose an algorithmic
approach to clear cell lesions of the salivary gland using
a limited set of immunohistochemical stains: pan-
cytokeratin, vimentin, calponin, and p63 (Fig. 3). Because
parotid metastases are overwhelmingly of cutaneous ori-
gin, melanoma should be a consideration in an otherwise
unspecified clear cell salivary gland lesion; a pan-
cytokeratin cocktail immunohistochemistry (e.g., AE1/
AE3/Cam5.2) will help to exclude melanoma (negative).
For lesions that are pan-cytokeratin positive, vimentin
immunohistochemistry will help separate acinic cell carci-
noma, clear cell carcinoma, and MEC (negative) from
other neoplasms. For these tumors, p63 immunohisto-
chemistry differentiates primary clear cell carcinoma
(positive) and MEC (positive in epidermoid cells) from
acinic cell carcinoma (negative). However, because onco-
cytomas are positive for p63 and variably negative for





Borghi et al. N N Unsatisfactory for
diagnosis
Sykes et al. N N Negative
Gangopadhyay et al. Y N Few malignant cells
Kundu et al. Y N Adenocarcinoma of
the parotid
Seijas et al. N N No evidence of
malignancy
Mrena et al. N N Pleomorphic adenoma






Stanley et al. Y Y
Stanley et al. Y Y
Li et al. N N Pleomorphic adenoma
Park and Hlivkio Y Y
G€og€us¸ et al. Y Y
Newton et al. N N Inconclusive
Mrena et al. Y Y
Mrena et al. Y Y
Spreafico et al. Y Y
Deeb et al. Y N Malignant lymphoma/
leukemiaa
Lau et al. N N Inconclusive
Udager and Rungta Y Y
(9 Y, 3 N) (8 Y, 4 N)
aPatient had a history of CLL.
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Fig. 2. Cytomorphologic features in the differential diagnosis of clear cell salivary gland lesions. (A and B) ThinPrep specimen of pleural fluid show-
ing metastatic RCC, clear cell type, 10003 magnification. Tumor cells are large and arranged in small, cohesive clusters; they have clear to finely
granular, “bubbly” cytoplasm with large nucleoli and conspicuous nucleoli. (C and D) ThinPrep specimen of a parotid mass FNAB showing metastatic
melanoma, 4003 and 10003 magnification. Tumor cells are predominantly in a single-cell pattern with occasional small, poorly cohesive clusters (C);
there is considerable pleomorphism, but many of the tumor cells have a plasmacytoid appearance with large nuclei (and/or binucleation) and prominent
nucleoli (D). (E) ThinPrep specimen of a parotid mass FNAB showing low-grade acinic cell carcinoma, 10003 magnification. The specimen is hyper-
cellular with numerous cohesive clusters of medium-sized, polygonal tumor cells; these cells have finely granular and/or vacuolated cytoplasm and
medium-sized nuclei with irregular nuclear membranes and variably prominent nucleoli. (F) An air-dried, Papanicolaou-stained smear of a parotid
mass FNAB showing an intermediate-grade mucoepidermoid carcinoma. The specimen is paucicellular with rare, small, cohesive clusters of medium-
sized tumor cells; these intermediate-type cells have variable amounts of finely granular cytoplasm and medium-sized nuclei without prominent nucle-
oli. Other areas of the slide showed abundant background mucin. (G and H) ThinPrep specimen and air-dried, Papanicolaou-stained smear, respec-
tively, of a parotid mass FNAB showing myoepithelial carcinoma. Tumor cells are predominantly arranged in small, cohesive clusters and finely
granular cytoplasm, pleomorphic nuclei with nuclear crowding (G) and irregular nuclear membranes (H), and conspicuous nucleoli. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
vimentin, phosphotungstic acid hematoxylin will help sep-
arate MEC and clear cell carcinoma (negative) from
oncocytoma (positive). Finally, mucin stains (i.e., muci-
carmine) will help distinguish between MEC (positive in
mucus-producing cells) and clear cell carcinoma
(negative).









Pleomorphic adenoma Parotid 1 1 1 1 1 2 Sensitive
Myoepithelioma Parotid 1 1 1 1 1 2 Sensitive
Oncocytoma Parotid 1 1/2 2 1 1 2 Sensitive PTAH
Malignant (primary)
Acinic cell carcinoma Parotid 1 2 2 2 1 2 Resistant PR, PSA, DOG1
Myoepithelial carcinoma Parotid 1 1 1 1 1 2 Sensitive
Epithelial–myoepithelial
carcinoma
Parotid 1 1 1 1 1a 2 Sensitive
Mucoepidermoid
carcinoma
Parotid 1 2 2 1b 1 2 Sensitive Mucin
(i.e., mucicarmine)




1 2 2 1 1 2 Sensitive CEA, EMA
Metastases
Renal cell carcinoma 1 1 2 2 2 Sensitive EMA, CD10,
RCC, Pax2, Pax8
Thyroid carcinoma 1 1 2 1 2 Sensitive TTF-1, thyroglobulin,
Pax2, Pax8
Melanoma 2 1 Melan-A, MITF,
tyrosinase, S-100
Assembled from Refs.:34, 38–45.
aCK7 staining in epithelial cells.
bp63 staining in squamoid cells.
Fig. 3. Proposed algorithmic approach to clear cell salivary gland lesions. Black boxes correspond to immunohistochemical or special stains. PTAH,
phosphotungstic acid hematoxylin; (1), positive; (-), negative; PA, pleomorphic adenoma; MC, myoepithelial carcinoma; EMC, epithelial–myoepithe-
lial carcinoma; MEC, mucoepidermoid carcinoma.
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For vimentin-positive, pan-cytokeratin-positive lesions,
calponin will help differentiate myoepithelial tumors
(positive) from metastatic clear cell carcinomas (nega-
tive). In addition, p63 immunohistochemistry helps sepa-
rate vimentin-positive oncocytomas (positive) from
metastatic clear cell carcinomas (negative). It should be
noted, however, that p63 is also a marker of myoepithe-
lial differentiation. Thus, in cases where calponin is nega-
tive but p63 is positive, it is important to still consider
the possibility of a myoepithelial lesion; immunohisto-
chemical confirmation with a third myoepithelial marker
(i.e., alpha smooth muscle actin) and/or correlation with
the cytomorphology are essential. Finally, CK7 immuno-
histochemistry will help localize potential metastatic clear
cell carcinomas, with most thyroid carcinomas positive
and most RCC negative. Initial algorithmic stratifications
should be followed by with confirmatory immunohisto-
chemical and/or special staining where appropriate
(Fig. 3). Using such an approach in our case would cor-
rectly identify the tumor as a likely parotid RCC metasta-
sis. Although it remains untested here, it would be
interesting to apply this algorithm prospectively to deter-
mine its effectiveness in classifying salivary gland clear
cell lesions.
In conclusion, although RCC is a rare metastatic
tumor of the parotid gland, there are important clinical
implications for the patient. It may alert the clinician to
an undiagnosed primary renal tumor and/or more wide-
spread metastases and, depending on the patient’s symp-
tomatology and overall clinical picture, guide the
decision making regarding surgical resection. Metastatic
parotid RCC can be a challenging diagnosis by FNAB;
there is a high rate of inadequate sampling, and the
clear cell type of RCC can mimic both primary and
other metastatic clear cell neoplasms. For otherwise non-
diagnostic cytologic specimens with small fragments of
tumor in a cell block preparation, focused immunohisto-
chemical and/or special staining may be essential for
diagnosis.
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